https://news.medxy.ai/zh/myelofibrosis-treatment-progress/Medxy AIzh2026-09-03T03:34:51-07:00骨髓纤维化治疗新进展：阿扎胞苷联合鲁可替尼II期研究最终结果积极 https://news.medxy.ai/ja/myelofibrosis-treatment-results/Medxy AIja2026-09-03T03:34:34-07:00骨髄線維症治療に新たな可能性：アザシチジン＋ルキソリチニブ第II相試験の最終結果 https://news.medxy.ai/vi/azacitidine-ruxolitinib-results/Medxy AIvi2026-09-03T03:34:16-07:00Kết quả cuối cùng pha II: Azacitidine phối hợp ruxolitinib cho thấy triển vọng trong điều trị xơ tủy xương https://news.medxy.ai/final-phase-ii-trial-results-azacitidine-plus-ruxolitinib-shows-promise-in-myelofibrosis-management/Medxy AIen2026-09-03T03:33:59-07:00Final Phase II Trial Results: Azacitidine plus Ruxolitinib Shows Promise in Myelofibrosis Management https://news.medxy.ai/zh/daratumumab-vcd-al-therapy/Medxy AIzh2026-09-03T03:33:19-07:00达雷妥尤单抗联合 VCd 显著改善新诊断 AL 淀粉样变生存结局：ANDROMEDA 试验揭示关键获益 https://news.medxy.ai/ja/d-vcd-effectiveness/Medxy AIja2026-09-03T03:33:02-07:00未治療ALアミロイドーシスの生存を有意に改善：ANDROMEDA試験が示したD-VCdの有効性 https://news.medxy.ai/vi/daratumumab-vcd-al-amyloidosis/Medxy AIvi2026-09-03T03:32:42-07:00Daratumumab phối hợp VCd giúp cải thiện sống còn rõ rệt ở AL amyloidosis mới chẩn đoán: Kết quả nổi bật từ thử nghiệm ANDROMEDA https://news.medxy.ai/daratumumab-vcd-combination-significantly-improves-survival-in-newly-diagnosed-al-amyloidosis-insights-from-the-andromeda-trial/Medxy AIen2026-09-03T03:32:23-07:00Daratumumab-VCd Combination Significantly Improves Survival in Newly Diagnosed AL Amyloidosis: Insights from the ANDROMEDA Trial https://news.medxy.ai/zh/mezigdomide-tcell-reversal/Medxy AIzh2026-09-03T03:31:42-07:00Mezigdomide通过IKZF1/IKZF3降解重塑细胞因子通路，逆转多发性骨髓瘤中的T细胞耗竭 https://news.medxy.ai/ja/mezigdomide-t-cell-activation/Medxy AIja2026-09-03T03:31:26-07:00MezigdomideがIKZF1/IKZF3分解を介してT細胞疲弊を解除し、多発性骨髄腫でサイトカイン経路を再活性化 https://news.medxy.ai/vi/mezigdomide-t-cell-exhaustion/Medxy AIvi2026-09-03T03:31:08-07:00Mezigdomide đảo ngược kiệt sức tế bào T trong đa u tủy thông qua thoái hóa IKZF1/IKZF3 và tái hoạt hóa con đường cytokine https://news.medxy.ai/mezigdomide-reverses-t-cell-exhaustion-through-ikzf1-ikzf3-degradation-and-cytokine-pathway-reinvigoration-in-multiple-myeloma/Medxy AIen2026-09-03T03:26:53-07:00Mezigdomide Reverses T-Cell Exhaustion Through IKZF1/IKZF3 Degradation and Cytokine Pathway Reinvigoration in Multiple Myeloma https://news.medxy.ai/zh/allo-hsct-septic-shock/Medxy AIzh2026-09-03T03:26:13-07:00异基因造血干细胞移植受者脓毒性休克：多中心ICU队列中的结局、预后因素及临床启示 https://news.medxy.ai/ja/septic-shock-transplant/Medxy AIja2026-09-03T03:25:48-07:00同種造血幹細胞移植レシピエントにおける敗血症性ショック：多施設ICUコホートからみた転帰・予後因子・臨床的含意 https://news.medxy.ai/vi/sepsis-after-stem-cell-transplant/Medxy AIvi2026-09-03T03:25:29-07:00Sốc nhiễm khuẩn sau ghép tế bào gốc tạo máu dị sinh: Kết cục, yếu tố tiên lượng và ý nghĩa lâm sàng từ một đoàn hệ ICU đa trung tâm https://news.medxy.ai/septic-shock-in-allogeneic-hematopoietic-stem-cell-transplant-recipients-outcomes-prognostic-factors-and-clinical-implications-from-a-multicenter-icu-cohort/Medxy AIen2026-09-03T03:25:09-07:00Septic Shock in Allogeneic Hematopoietic Stem-Cell Transplant Recipients: Outcomes, Prognostic Factors, and Clinical Implications from a Multicenter ICU Cohort https://news.medxy.ai/zh/vexus-right-atrial-pressure/Medxy AIzh2026-09-03T03:24:31-07:00肺动脉高压中右心房压评估的VExUS验证：一项多中心研究 https://news.medxy.ai/ja/vexus-right-atrial-pressure-2/Medxy AIja2026-09-03T03:24:14-07:00肺高血圧症における右房圧評価へVExUSは有用か——多施設研究で検証 https://news.medxy.ai/vi/vexus-assessment/Medxy AIvi2026-09-03T03:23:55-07:00Thẩm định VExUS để đánh giá áp lực nhĩ phải trong tăng áp động mạch phổi: nghiên cứu đa trung tâm https://news.medxy.ai/validating-the-venous-excess-ultrasound-score-vexus-for-right-atrial-pressure-assessment-in-pulmonary-hypertension-a-multicenter-study/Medxy AIen2026-09-03T03:23:36-07:00Validating the Venous Excess Ultrasound Score (VExUS) for Right Atrial Pressure Assessment in Pulmonary Hypertension: A Multicenter Study https://news.medxy.ai/zh/head-neck-cancer-care/Medxy AIzh2026-09-03T03:22:57-07:00为头颈癌患者赋能：新型亚专科门诊姑息照护诊所的实践启示 https://news.medxy.ai/ja/head-neck-cancer-care-2/Medxy AIja2026-09-03T03:22:41-07:00頭頸部癌患者のケアを高める：新規サブスペシャルティ外来緩和医療クリニックから得られた知見 https://news.medxy.ai/enhancing-care-for-head-and-neck-cancer-patients-insights-from-a-novel-subspecialty-outpatient-palliative-medicine-clinic/Medxy AIen2026-09-03T03:22:06-07:00Enhancing Care for Head and Neck Cancer Patients: Insights from a Novel Subspecialty Outpatient Palliative Medicine Clinic https://news.medxy.ai/metabolite-mediated-neurocognitive-revival-following-liver-transplantation-insights-into-cortical-network-reactivation/Medxy AIen2026-09-03T00:08:00-07:00Metabolite-Mediated Neurocognitive Revival Following Liver Transplantation: Insights into Cortical Network Reactivation https://news.medxy.ai/zh/stylegan3-synth-video/Medxy AIzh2026-09-02T23:21:33-07:00StyleGAN3 生成的合成视频频闪镜喉部图像：真实性评估 https://news.medxy.ai/ja/stylegan3-video-realism/Medxy AIja2026-09-02T23:21:11-07:00StyleGAN3で生成した合成ビデオストロボスコピー喉頭画像のリアリズム評価 https://news.medxy.ai/vi/stylegan3-videostroboscopy/Medxy AIvi2026-09-02T23:20:52-07:00Đánh giá tính chân thực của hình ảnh thanh quản videostroboscopy tổng hợp do StyleGAN3 tạo ra https://news.medxy.ai/evaluating-realism-in-synthetic-videostroboscopic-laryngeal-images-generated-by-stylegan3/Medxy AIen2026-09-02T23:20:33-07:00Evaluating Realism in Synthetic Videostroboscopic Laryngeal Images Generated by StyleGAN3 https://news.medxy.ai/zh/redefining-disability-thresholds/Medxy AIzh2026-09-02T23:19:51-07:00重新界定功能状态量表阈值，提升儿童创伤患者残疾识别率 https://news.medxy.ai/ja/functional-status-thresholds/Medxy AIja2026-09-02T23:19:34-07:00小児外傷の障害検出を高めるためのFunctional Status Scale閾値の見直し https://news.medxy.ai/vi/adjust-fss-threshold/Medxy AIvi2026-09-02T23:19:16-07:00Điều chỉnh ngưỡng FSS để phát hiện khuyết tật tốt hơn ở trẻ em chấn thương https://news.medxy.ai/redefining-functional-status-scale-thresholds-to-improve-disability-detection-in-pediatric-trauma-patients/Medxy AIen2026-09-02T23:18:57-07:00Redefining Functional Status Scale Thresholds to Improve Disability Detection in Pediatric Trauma Patients https://news.medxy.ai/zh/11-oxoandrogens-pcos/Medxy AIzh2026-09-02T23:18:22-07:00揭示11-氧代雄激素在PCOS中的作用：表型特异性谱系与治疗反应 https://news.medxy.ai/ja/pcos-11-oxygenated-androgens/Medxy AIja2026-09-02T23:15:06-07:00PCOSにおける11-酸素化アンドロゲンの実像：表現型別プロファイルと治療反応 https://news.medxy.ai/vi/androgen-11-oxy-pcos/Medxy AIvi2026-09-02T23:13:50-07:00Androgen 11-oxy hóa trong PCOS: khác biệt theo kiểu hình và đáp ứng điều trị https://news.medxy.ai/unraveling-the-role-of-11-oxygenated-androgens-in-pcos-phenotype-specific-profiles-and-treatment-responses/Medxy AIen2026-09-02T23:13:30-07:00Unraveling the Role of 11-Oxygenated Androgens in PCOS: Phenotype-Specific Profiles and Treatment Responses https://news.medxy.ai/zh/finerenone-ckd/Medxy AIzh2026-09-02T23:12:47-07:00Finerenone在高血压性非糖尿病慢性肾脏病中的应用：FIND-CKD亚组分析新证据 https://news.medxy.ai/ja/finerenone-ckd-evidence/Medxy AIja2026-09-02T23:12:28-07:00高血圧性非糖尿病性CKDにおけるフィネレノン：FIND-CKDサブグループ解析が示すエビデンス https://news.medxy.ai/vi/finerenone-ckd-hypertension/Medxy AIvi2026-09-02T23:12:07-07:00Finerenone trong bệnh thận mạn không do đái tháo đường kèm tăng huyết áp: Bằng chứng từ phân tích dưới nhóm FIND-CKD https://news.medxy.ai/finerenone-in-hypertensive-non-diabetic-chronic-kidney-disease-evidence-from-the-find-ckd-subgroup-analysis/Medxy AIen2026-09-02T23:11:49-07:00Finerenone in Hypertensive Non-Diabetic Chronic Kidney Disease: Evidence from the FIND-CKD Subgroup Analysis https://news.medxy.ai/ja/cardiovascular-burden-cancer-diagnosis/Medxy AIja2026-09-02T23:10:53-07:00がん診断時に増える心血管疾患負担：イングランド全国コホートが示す実態と将来予測 https://news.medxy.ai/vi/cardiovascular-burden-cancer/Medxy AIvi2026-09-02T23:10:34-07:00Gánh nặng bệnh tim mạch tại thời điểm chẩn đoán ung thư gia tăng: Bằng chứng từ một đoàn hệ quốc gia ở Anh và dự báo tương lai https://news.medxy.ai/rising-cardiovascular-disease-burden-at-cancer-diagnosis-insights-from-a-national-english-cohort-and-future-projections/Medxy AIen2026-09-02T23:10:16-07:00Rising Cardiovascular Disease Burden at Cancer Diagnosis: Insights from a National English Cohort and Future Projections https://news.medxy.ai/zh/vutrisiran-efficacy/Medxy AIzh2026-09-02T23:09:37-07:00Vutrisiran在转甲状腺素蛋白淀粉样变性心肌病中的疗效稳定，合并治疗不影响获益 https://news.medxy.ai/ja/vitrisislan-efficacy/Medxy AIja2026-09-02T23:09:20-07:00背景治療に左右されないビトリシランの有効性：トランスサイレチン心アミロイドーシス治療の新たな示唆 https://news.medxy.ai/vi/vutrisiran-effectiveness/Medxy AIvi2026-09-02T23:09:03-07:00Vutrisiran duy trì hiệu quả nhất quán trong bệnh cơ tim amyloid transthyretin dù dùng kèm các liệu pháp điều trị khác https://news.medxy.ai/consistent-efficacy-of-vutrisiran-in-transthyretin-cardiac-amyloidosis-amidst-concomitant-disease-modifying-therapies/Medxy AIen2026-09-02T23:08:46-07:00Consistent Efficacy of Vutrisiran in Transthyretin Cardiac Amyloidosis Amidst Concomitant Disease-Modifying Therapies https://news.medxy.ai/zh/tavr-paradox/Medxy AIzh2026-09-02T23:08:05-07:00矛盾性低流量、低梯度主动脉瓣狭窄中的经导管主动脉瓣置换术：REBOOT-PARADOX试验的新启示 https://news.medxy.ai/ja/paradoxical-asortic-stenosis/Medxy AIja2026-09-02T23:07:47-07:00逆説的低流量・低圧較差大動脈弁狭窄症に対する経カテーテル大動脈弁置換術――REBOOT-PARADOX試験から見えた臨床的示唆 https://news.medxy.ai/vi/aortic-valve-catheterization/Medxy AIvi2026-09-02T23:07:26-07:00Thay van động mạch chủ qua ống thông ở hẹp van động mạch chủ dòng chảy thấp, chênh áp thấp nghịch lý: Các phát hiện từ thử nghiệm REBOOT-PARADOX https://news.medxy.ai/transcatheter-aortic-valve-replacement-in-paradoxical-low-flow-low-gradient-aortic-stenosis-insights-from-the-reboot-paradox-trial/Medxy AIen2026-09-02T23:07:06-07:00Transcatheter Aortic Valve Replacement in Paradoxical Low-Flow, Low-Gradient Aortic Stenosis: Insights from the REBOOT-PARADOX Trial https://news.medxy.ai/zh/aficamten-hcm/Medxy AIzh2026-09-02T23:06:24-07:00Aficamten改善有症状非梗阻性肥厚型心肌病的心脏功能与结构：来自ACACIA-HCM试验的启示 https://news.medxy.ai/ja/aficamten-hcm-effects/Medxy AIja2026-09-02T23:06:06-07:00症候性非閉塞性肥大型心筋症におけるAficamtenの心機能・心構造への影響：ACACIA-HCM試験からの知見 https://news.medxy.ai/aficamtens-impact-on-cardiac-function-and-structure-in-symptomatic-nonobstructive-hypertrophic-cardiomyopathy-insights-from-acacia-hcm-trial/Medxy AIen2026-09-02T23:05:28-07:00Aficamten’s Impact on Cardiac Function and Structure in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy: Insights from ACACIA-HCM Trial https://news.medxy.ai/zh/azd5462-heart-failure/Medxy AIzh2026-09-02T23:04:44-07:00口服 relaxin 受体激动剂 AZD5462 在慢性心力衰竭中展现潜力：LUMINARA 试验解读 https://news.medxy.ai/ja/69955-2/Medxy AIja2026-09-02T23:04:28-07:00経口リラキシン受容体作動薬AZD5462が慢性心不全において可能性を示す：LUMINARA試験からの知見 https://news.medxy.ai/vi/69954-2/Medxy AIvi2026-09-02T23:04:08-07:00Thuốc chủ vận thụ thể relaxin dùng đường uống AZD5462 cho thấy tiềm năng trong điều trị suy tim mạn tính: Những thông tin từ thử nghiệm LUMINARA https://news.medxy.ai/oral-relaxin-receptor-agonist-azd5462-shows-promise-in-chronic-heart-failure-insights-from-the-luminara-trial/Medxy AIen2026-09-02T23:03:48-07:00Oral Relaxin Receptor Agonist AZD5462 Shows Promise in Chronic Heart Failure: Insights from the LUMINARA Trial https://news.medxy.ai/zh/69926-2/Medxy AIzh2026-09-02T22:42:09-07:00“开放式对话”与“常规治疗”，哪个对成年人心理健康危机更有效？ https://news.medxy.ai/zh/post-weight-loss-surgery-risks/Medxy AIzh2026-09-02T22:39:03-07:00减重后体形塑造手术并发症风险评估：手术、GLP-1药物、联合治疗与生活方式干预的比较 https://news.medxy.ai/ja/body-contouring-complications/Medxy AIja2026-09-02T22:35:00-07:00減量後ボディ・コントゥアリングの合併症率を検証：手術、GLP-1薬物療法、併用療法、生活習慣介入の比較 https://news.medxy.ai/vi/complication-rates-post-body-contouring/Medxy AIvi2026-09-02T22:33:17-07:00Đánh giá tỷ lệ biến chứng sau tạo hình đường nét cơ thể ở bệnh nhân đã giảm cân: so sánh phẫu thuật, điều trị GLP-1, phối hợp và thay đổi lối sống https://news.medxy.ai/evaluating-complication-rates-in-post-weight-loss-body-contouring-comparing-surgery-glp-1-pharmacotherapy-combination-and-lifestyle-approaches/Medxy AIen2026-09-02T22:31:49-07:00Evaluating Complication Rates in Post-Weight-Loss Body Contouring: Comparing Surgery, GLP-1 Pharmacotherapy, Combination, and Lifestyle Approaches https://news.medxy.ai/ja/body-contouring-outcomes/Medxy AIja2026-09-02T06:00:59-07:00減量法は術後成績に影響するか？肥満手術後のボディ・コントゥアリング手術転帰を比較する https://news.medxy.ai/vi/weight-loss-surgery-impact/Medxy AIvi2026-09-02T06:00:32-07:00Tác động của phương pháp giảm cân đến kết quả phẫu thuật tạo hình đường nét cơ thể sau giảm béo: phân tích so sánh https://news.medxy.ai/impact-of-weight-loss-methods-on-post-bariatric-body-contouring-surgery-outcomes-a-comparative-analysis/Medxy AIen2026-09-02T06:00:15-07:00Impact of Weight-Loss Methods on Post-Bariatric Body Contouring Surgery Outcomes: A Comparative Analysis https://news.medxy.ai/zh/facelift-age-risks-2/Medxy AIzh2026-09-02T05:59:21-07:00面部提升术的年龄相关风险如何评估：实际年龄真的是障碍吗？ https://news.medxy.ai/ja/facelift-age-risks/Medxy AIja2026-09-02T05:59:02-07:00フェイスリフト手術における年齢関連リスクを検証：暦年齢は障壁となるのか https://news.medxy.ai/vi/age-risk-facelift/Medxy AIvi2026-09-02T05:58:40-07:00Đánh giá nguy cơ theo tuổi trong phẫu thuật căng da mặt: Liệu tuổi theo niên lịch có phải là rào cản? https://news.medxy.ai/assessing-age-related-risks-in-facelift-surgery-is-chronological-age-a-barrier/Medxy AIen2026-09-02T05:57:58-07:00Assessing Age-Related Risks in Facelift Surgery: Is Chronological Age a Barrier? https://news.medxy.ai/zh/hidden-costs-nerves/Medxy AIzh2026-09-02T05:57:15-07:00治愈背后的隐性成本：远端上肢神经损伤后的经济负担 https://news.medxy.ai/ja/hidden-burdens/Medxy AIja2026-09-02T05:56:57-07:00治癒の裏にある見えない負担：遠位上肢神経損傷後の経済的苦難 https://news.medxy.ai/vi/silent-financial-burden/Medxy AIvi2026-09-02T05:56:31-07:00Gánh nặng tài chính âm thầm sau tổn thương thần kinh chi trên đoạn xa https://news.medxy.ai/hidden-costs-of-healing-financial-burdens-after-distal-upper-extremity-nerve-injuries/Medxy AIen2026-09-02T05:56:02-07:00Hidden Costs of Healing: Financial Burdens After Distal Upper Extremity Nerve Injuries https://news.medxy.ai/a-split-muscle-support-technique-for-direct-to-implant-breast-reconstruction-a-case-series/Medxy AIen2026-09-02T05:55:19-07:00A Split-Muscle Support Technique for Direct-To-Implant Breast Reconstruction: A Case Series https://news.medxy.ai/ja/69683-2/Medxy AIja2026-09-02T05:18:43-07:00イングランドにおける成人向けメンタルヘルス・クライシス・ケア：オープン・ダイアローグ対通常の治療――ODDESSI多施設共同クラスター無作為化試験の分析 https://news.medxy.ai/vi/open-dialogue-treatment/Medxy AIvi2026-09-02T05:17:58-07:00Open Dialogue hay điều trị thường quy: Góc nhìn từ thử nghiệm ngẫu nhiên theo cụm đa trung tâm ODDESSI ở Anh https://news.medxy.ai/open-dialogue-versus-treatment-as-usual-for-adults-in-mental-health-crisis-insights-from-the-oddessi-multisite-cluster-randomised-trial-in-england/Medxy AIen2026-09-02T05:17:39-07:00Open Dialogue versus Treatment as Usual for Adults in Mental Health Crisis: Insights from the ODDESSI Multisite Cluster-Randomised Trial in England https://news.medxy.ai/zh/genomics-psychiatry-prevention/Medxy AIzh2026-09-02T05:16:51-07:00基因组学如何助力精神病学精准预防：机遇与挑战 https://news.medxy.ai/ja/69678-2/Medxy AIja2026-09-02T05:16:33-07:00精神医学におけるゲノミクスと精密予防の推進：機会と課題 https://news.medxy.ai/vi/genomics-precision-psychiatry/Medxy AIvi2026-09-02T05:16:12-07:00Khai thác genomics để phòng ngừa chính xác trong tâm thần học: cơ hội và thách thức https://news.medxy.ai/harnessing-genomics-for-precision-prevention-in-psychiatry-opportunities-and-challenges/Medxy AIen2026-09-02T05:15:46-07:00Harnessing Genomics for Precision Prevention in Psychiatry: Opportunities and Challenges https://news.medxy.ai/zh/glp-1-cardiovascular-outcomes/Medxy AIzh2026-09-02T05:14:55-07:00GLP-1受体激动剂、死亡率与重性精神障碍患者的心血管结局：一项综合性综述 https://news.medxy.ai/ja/glp-1-mortality-review/Medxy AIja2026-09-02T05:14:31-07:00重篤な精神疾患におけるGLP-1受容体作動薬の死亡率と心血管転帰：包括的レビュー https://news.medxy.ai/vi/glp1-agonists-mental-illness/Medxy AIvi2026-09-02T05:14:07-07:00Thuốc chủ vận thụ thể GLP-1 trong bệnh tâm thần nặng: Tử vong và kết cục tim mạch dưới góc nhìn tổng quan toàn diện https://news.medxy.ai/glucagon-like-peptide-1-receptor-agonists-mortality-and-cardiovascular-outcomes-in-serious-mental-illness-a-comprehensive-review/Medxy AIen2026-09-02T05:13:43-07:00Glucagon-Like Peptide 1 Receptor Agonists, Mortality, and Cardiovascular Outcomes in Serious Mental Illness: A Comprehensive Review https://news.medxy.ai/zh/early-activity-icu-outcomes/Medxy AIzh2026-09-01T05:12:41-07:00早期活动能否改善机械通气脓毒症或急性呼吸衰竭ICU患者结局？——EVER多中心随机对照试验的启示 https://news.medxy.ai/ja/early-mobilization-sepsis/Medxy AIja2026-09-01T05:12:21-07:00敗血症・急性呼吸不全の人工呼吸管理患者における早期離床の効果を検証――EVER多施設RCTからの示唆 https://news.medxy.ai/vi/early-mobilization-icu/Medxy AIvi2026-09-01T05:11:59-07:00Vận động sớm ở bệnh nhân ICU thở máy mắc nhiễm khuẩn huyết hoặc suy hô hấp cấp: Những phát hiện từ thử nghiệm ngẫu nhiên đa trung tâm EVER https://news.medxy.ai/evaluating-the-impact-of-early-mobilization-in-mechanically-ventilated-icu-patients-with-sepsis-or-acute-respiratory-failure-insights-from-the-ever-multicenter-rct/Medxy AIen2026-09-01T05:11:38-07:00Evaluating the Impact of Early Mobilization in Mechanically Ventilated ICU Patients with Sepsis or Acute Respiratory Failure: Insights from the EVER Multicenter RCT https://news.medxy.ai/zh/69664-2/Medxy AIzh2026-09-01T05:10:56-07:00美国儿科重症监护二十年来的演变：基于ICU收治量上升与区域整合对医疗卫生系统的启示 https://news.medxy.ai/ja/us-pediatric-icu-trends/Medxy AIja2026-09-01T05:10:38-07:00米国小児重症医療の20年の変遷：ICU入室増加と地域集約化が示す医療体制への示唆 https://news.medxy.ai/vi/pediatric-icu-trends/Medxy AIvi2026-09-01T05:10:18-07:00Xu hướng thay đổi của chăm sóc hồi sức tích cực nhi khoa tại Hoa Kỳ giai đoạn 2001–2022: Hàm ý đối với năng lực y tế và khu vực hóa https://news.medxy.ai/evolving-trends-in-pediatric-critical-care-in-the-u-s-from-2001-to-2022-implications-for-healthcare-capacity-and-regionalization/Medxy AIen2026-09-01T05:09:58-07:00Evolving Trends in Pediatric Critical Care in the U.S. from 2001 to 2022: Implications for Healthcare Capacity and Regionalization https://news.medxy.ai/zh/icu-acute-hypoxemic-failure/Medxy AIzh2026-09-01T05:09:08-07:00ICU 患者急性低氧性呼吸衰竭：流行病学、通气管理与结局——一项多 ICU 队列研究 https://news.medxy.ai/ja/icu-acute-hypoxemic-respiratory-failure/Medxy AIja2026-09-01T05:08:53-07:00ICU患者における急性低酸素性呼吸不全を読み解く：多施設コホート研究が示す疫学、換気管理、転帰 https://news.medxy.ai/vi/acute-respiratory-failure/Medxy AIvi2026-09-01T05:08:34-07:00Hiểu đúng suy hô hấp giảm oxy máu cấp tính ở bệnh nhân ICU: dịch tễ học, quản lý thông khí và kết cục từ một nghiên cứu đoàn hệ đa ICU https://news.medxy.ai/understanding-acute-hypoxemic-respiratory-failure-in-icu-patients-epidemiology-ventilatory-management-and-outcomes-from-a-multi-icu-cohort-study/Medxy AIen2026-09-01T05:08:14-07:00Understanding Acute Hypoxemic Respiratory Failure in ICU Patients: Epidemiology, Ventilatory Management, and Outcomes from a Multi-ICU Cohort Study https://news.medxy.ai/zh/69644-2/Medxy AIzh2026-09-01T05:07:29-07:00COVID-19 后的长期医疗服务利用：基于初始感染严重程度的差异化模式 https://news.medxy.ai/ja/69642-2/Medxy AIja2026-09-01T05:07:09-07:00COVID-19後の長期的な医療利用：初期感染の重症度に基づく多様なパターン https://news.medxy.ai/vi/post-covid-healthcare-changes/Medxy AIvi2026-09-01T05:06:48-07:00Sau COVID-19, việc sử dụng dịch vụ y tế thay đổi ra sao? Khác biệt rõ theo mức độ nặng ban đầu https://news.medxy.ai/long-term-healthcare-utilization-after-covid-19-varied-patterns-based-on-initial-infection-severity/Medxy AIen2026-09-01T05:06:28-07:00Long-Term Healthcare Utilization After COVID-19: Varied Patterns Based on Initial Infection Severity https://news.medxy.ai/zh/diabetes-followup-challenges/Medxy AIzh2026-09-01T05:05:46-07:00急诊出院后如何接上门诊照护：糖尿病患者随访现状与挑战 https://news.medxy.ai/ja/supporting-diabetes-patients/Medxy AIja2026-09-01T05:05:28-07:00救急外来退院後の糖尿病患者をどう支えるか：外来フォローアップの確保に向けて https://news.medxy.ai/vi/discharge-diabetes-followup/Medxy AIvi2026-09-01T05:05:11-07:00Sau xuất viện từ khoa cấp cứu vì đái tháo đường: Làm sao bảo đảm người bệnh được tái khám ngoại trú đúng hẹn? https://news.medxy.ai/bridging-the-gap-ensuring-outpatient-follow-up-after-emergency-department-visits-for-diabetes/Medxy AIen2026-09-01T05:04:52-07:00Bridging the Gap: Ensuring Outpatient Follow-Up After Emergency Department Visits for Diabetes https://news.medxy.ai/zh/prostate-cancer-cardiovascular-referral/Medxy AIzh2026-09-01T05:04:15-07:00前列腺癌患者转诊心血管专科有助于改善胆固醇管理：全球随机试验带来的启示 https://news.medxy.ai/ja/cardiologist-referral/Medxy AIja2026-09-01T05:03:58-07:00前立腺がん患者のコレステロール管理を高める心血管専門医紹介――国際ランダム化試験からの知見 https://news.medxy.ai/vi/69619-2/Medxy AIvi2026-09-01T05:03:39-07:00Chuyển bệnh nhân ung thư tuyến tiền liệt sang bác sĩ tim mạch để cải thiện việc kiểm soát cholesterol: Những hiểu biết từ một thử nghiệm ngẫu nhiên quốc tế https://news.medxy.ai/specialist-cardiovascular-referral-enhances-cholesterol-management-in-prostate-cancer-patients-insights-from-a-global-randomized-trial/Medxy AIen2026-09-01T05:03:20-07:00Specialist Cardiovascular Referral Enhances Cholesterol Management in Prostate Cancer Patients: Insights from a Global Randomized Trial